ETNB 89bio
- 7.350
- -0.050-0.68%
- 7.360
- +0.010+0.14%
89bio News
89bio Analyst Ratings
Cantor Fitzgerald Reiterates Overweight on 89bio, Maintains $29 Price Target
Cantor Fitzgerald Maintains 89bio(ETNB.US) With Buy Rating, Cuts Target Price to $29
Evercore Maintains 89bio(ETNB.US) With Buy Rating, Maintains Target Price $33
Analysts Offer Insights on Healthcare Companies: Janux Therapeutics Inc (JANX), 89bio (ETNB) and Ardent Health Partners, Inc. (ARDT)
H.C. Wainwright Maintains 89bio(ETNB.US) With Buy Rating, Maintains Target Price $29
HC Wainwright & Co. Reiterates Buy on 89bio, Maintains $29 Price Target
89bio Analyst Ratings
Raymond James Maintains Strong Buy on 89bio, Lowers Price Target to $49
RBC Capital Maintains 89bio(ETNB.US) With Hold Rating, Maintains Target Price $12
89bio (ETNB) Gets a Hold From RBC Capital
89bio Analyst Ratings
Cantor Fitzgerald Reiterates Overweight on 89bio, Maintains $29 Price Target
Leerink Partners Maintains 89bio(ETNB.US) With Buy Rating, Maintains Target Price $34
Buy Rating Affirmed for 89bio: Promising Pegozafermin Trials and Regulatory Confidence
89bio Price Target Raised to $53.00/Share From $50.00 by Raymond James
RBC Capital Maintains Sector Perform on 89bio, Lowers Price Target to $12
Evercore Maintains 89bio(ETNB.US) With Buy Rating, Maintains Target Price $33
RBC Capital Maintains 89bio(ETNB.US) With Hold Rating, Cuts Target Price to $12
89bio (ETNB) Receives a Hold From RBC Capital
No Data